Cogentus Pharma Raising Series C

Cogentus Pharmaceuticals Inc., a Menlo Park, Calif.-based developer of antiplatelet therapies for cardiovascular disease, has secured $7.5 million of a $22.5 million Series C round, according to a regulatory filing. Listed backers include Keffi Group, Prospect Venture Partners and Ridgeback Capital. The company had previously raised over $62 million.